hodgkin's%20lymphoma
HODGKIN'S LYMPHOMA

Hodgkin's lymphoma is a malignancy that arises from germinal center B cell.

Histologically, there is a presence of multinucleated giant cells in a mixed inflammatory background.

It is also known as Hodgkin's disease, Hodgkin lymphoma or Hodgkin disease.

It commonly affects individuals ages 15-30 years old and those 55 years old and above.

The key morphologic characteristics include presence of Reed-Sternberg cells and lymphocyte-predominant cells.

Hodgkin's%20lymphoma Management

Follow Up

Tests After Completion of Initial Therapy

  • Restaging via PET-CT scan should be done after completion of chemotherapy, based on the Deauville criteria
    • Favorable, unfavorable & aggressive classic Hodgkin lymphoma (CHL) restaging should be based on the Deauville criteria
    • Restaging of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) patients is recommended after completion of initial therapy
  • PET 5-Point Scale (Deauville Criteria)

  • Score PET-CT scan result
    1 No uptake
    2 Uptake ≤ mediastinum
    3 Uptake > mediastinum but ≤ liver
    4 Uptake moderately higher than the liver
    5 Uptake markedly higher than the liver &/or new lesions
    X New areas of uptake unlikely to be related to lymphoma
  • Biopsy & PET-CT scan may be requested for patients with Deauville 4-5 score after completion of therapy
  • CT scan with contrast of the neck, chest, abdomen, & pelvis may be requested at 6, 12 & 24 months after completion of therapy or as clinically indicated
  • Other imaging studies of initially involved sites (eg ultrasonography, chest radiography) may be repeated
  • The following should be tested annually 5 years after therapy completion:
    • Blood pressure
    • Complete blood count (CBC), platelets, chemistry profile
    • Thyroid Stimulating hormone (TSH) (for patients with radiotherapy to the neck)
    • Lipid profile (2x/year)
    • Fasting glucose yearly
    • Annual breast examination with mammography & magnetic resonance imaging (MRI) are advised for women previously irradiated at the chest or axillary area
    • Colonoscopy every 10 years for patients >50 years old

Timing of Follow-up

  • Yearly follow-up should be advised for the first 5 years after treatment
  • Patients should undergo complete history taking & physical examination every 3-6 months for 1-2 years, then every 6-12 months until year 3 & then yearly
  • Thorough physical examination & psychologic evaluation is recommended every 4-6 month for the first 5 years
  • CBC, platelet count, erythrocyte sedimentation rate (ESR), & chemistry profile should be obtained as clinically indicated
  • Physical exams & blood tests (CBC, ESR, blood chemistry) should be done for NLPHL patients every 3-6 months for 1-2 years, then every 6-12 months for the next 3 years, then annually
  • A low-dose computed tomography (CT) scan of chest may be requested after 5 years for patients at increased risk for lung cancer & have undergone treatment with non-alkylating chemotherapeutic agents, no previous radiation therapy, & no other risk factors
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Pearl Toh, 6 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Elvira Manzano, 17 Nov 2020
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.